Sareum (LON:SAR – Get Free Report) issued its quarterly earnings results on Monday. The company reported GBX (2.40) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
Sareum Stock Down 2.0%
LON:SAR opened at GBX 15.12 on Monday. Sareum has a 52-week low of GBX 11.75 and a 52-week high of GBX 40. The stock has a fifty day simple moving average of GBX 29.46 and a 200-day simple moving average of GBX 22.38. The company has a market capitalization of £21.12 million, a PE ratio of -3.88 and a beta of -1.08.
Sareum Company Profile
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Read More
- Five stocks we like better than Sareum
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
